New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:36 EDTACHNAchillion equity offering reduces finance concerns, says RW Baird at RW Baird
Baird believes Achillion's secondary offering will reduce concerns surrounding its finances and remains bullish on the shares. The firm noted the company's guidance and pipeline updates and believes the shares are at an attractive entry point. Baird continues to believe Achillion will play a meaningful role in the Hep commercial landscape. Shares are Outperform rated with a $16 price target.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
16:02 EDTACHNOptions Update; December 22, 2014
Subscribe for More Information
14:20 EDTACHNAchillion price target raised to $25 from $17 at Deutsche Bank
Subscribe for More Information
12:18 EDTACHNOn The Fly: Midday Wrap
Subscribe for More Information
11:13 EDTACHNAchillion price target raised to $22.50 from $12 at Piper Jaffray
Subscribe for More Information
11:00 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
09:29 EDTACHNAchillion nuc 'looks less potent' than others, says Wells Fargo
Wells Fargo says Achillion's nuc '3422 "looks less potent" than others in development but still potentially viable. The firm, however, believes the NS5A data suggests best-in-class profile for Achillion's '3102. Wells expects the stock to be up after this morning's data and keeps an Outperform rating on the name.
06:40 EDTACHNAchillion to host conference call
Conference call to discuss positive results from two studies supporting a short duration, of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422 will be held on December 22 at 8:30 am. Webcast Link
06:36 EDTACHNAchillion announces positive interim results for NS5A, ACH-3102
Achillion Pharmaceuticals announced positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422. Achillion announced 100% SVR4 results from the ongoing six-week trial. This study is an interferon-free, ribavirin-free, Phase 2 open-label, randomized study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, once daily, in treatment-na´ve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks after completion of therapy. Achillion also announced today interim study results demonstrating that ACH-3422 achieved proof-of-concept in a Phase 1 trial for patients with treatment-na´ve genotype 1 HCV. In the 700 mg dose group, mean maximal reduction in HCV viral RNA load of 4.8 log10 IU/ml was observed within 14 days with 3 out of 6 patients achieving undetectable HCV RNA. The pharmacodynamic characteristics of ACH-3422 provided sustained antiviral activity resulting in an additional 1.4 log10 reduction in HCV RNA between day 7 and day 14 of dosing.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN HLF
Stocks with implied volatility above IV index mean; Achillion (ACHN) 265, Herbalife (HLF) 76 according to iVolatility.
December 19, 2014
06:09 EDTACHNStocks with implied volatility above IV index mean; RSH ACHN
Stocks with implied volatility above IV index mean; RadioShack (RSH) 278, Achillion (ACHN) 269 according to iVolatility.
December 18, 2014
12:58 EDTACHNAchillion December weekly volatility elevated at 290
Achillion December call option implied volatility is at 205, December weekly at 290, January is at 263; compared to its 26-week average of 156 according to Track Data, suggesting large price movement.
06:00 EDTACHNStocks with implied volatility movement; DO ACHN
Stocks with implied volatility movement; Diamond Offshore (DO) 93, Achillion (ACHN) 285 according to iVolatility.
December 15, 2014
13:06 EDTACHNAchillion December volatility elevated at 285
Achillion December call option implied volatility is at 285, January is at 231; compared to its 26-week average of 153 according to Track Data, suggesting large price movement.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN DG
Subscribe for More Information
December 8, 2014
11:49 EDTACHNAchillion December volatility elevated
Subscribe for More Information
08:32 EDTACHNTrout Group to hold events at ASH 2014
Subscribe for More Information
06:12 EDTACHNStocks with implied volatility above IV index mean; LULU ACHN
Stocks with implied volatility above IV index mean; lululemon (LULU) 53, Achillion (ACHN) 216 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use